Phio reports complete response in cSCC and manufacturing agreement for PH-762

Phio Pharmaceuticals Corp.

Entered into comprehensive drug substance development agreement with U.S. manufacturer for PH-762.
Phase 1b fourth-cohort: one complete pathologic response (100% tumor clearance) in cSCC patient.
One partial response (>50% clearance) in stage 4 metastatic Merkel cell; two non-responses in cSCC.
No dose-limiting toxicities; PH-762 well tolerated across all cohorts; no clinical progression.
Enrolling 5th and expected final cohort in Phase 1b dose escalation study for cutaneous carcinomas.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.